‘A tax on being thin’: only high earners make overall savings on food bills from weight-loss drugs

The weight-loss drug boom has a new side effect nobody put on the label: it's a regressive tax on the waistline. The Guardian's analysis finds the £1,200 annual price tag for GLP-1s only pencils out for those with nearly £100,000 in discretionary income. For everyone else, the math is simple — you pay more for the medication than you'll ever save at the grocery checkout. That's not a health breakthrough; that's a means test. Why it matters: this isn't just about appetite suppression. It signals a two-tier system where the "cure" for obesity — and its associated cost-of-living relief — is reserved for the affluent. The same drugs that promise to slash food bills are structurally out of reach for the families who feel grocery inflation most keenly. The irony is thick enough to spread on toast. The consultancy's numbers strip the fantasy from the marketing. Weight-loss drugs don't save you money; they cost you more, unless you're already rich. So the real question facing regulators isn't efficacy — it's equity. In the end, the scale tips only for those who don't need it. Being thin was never cheap; now it's an investment portfolio. {"key_insight":"The economics of GLP-1s create a wealth barrier that turns weight loss into a privilege, not a public health solution.","confidence":0}